458 related articles for article (PubMed ID: 11216521)
1. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
2. Bone uptake studies in rabbits before and after high-dose treatment with 153Sm-EDTMP or 186Re-HEDP.
Brenner W; Kampen WU; Brümmer C; von Forstner C; Zuhayra M; Czech N; Muhle C; Henze E
J Nucl Med; 2003 Feb; 44(2):247-51. PubMed ID: 12571217
[TBL] [Abstract][Full Text] [Related]
3. Radiation safety considerations for the bone seeking radiopharmaceuticals. 89SrCl2, 186Re-HEDP and 153Sm-EDTMP.
Lam MG; Hoekstra A; de Klerk JM; van Rijk PP; Zonnenberg BA
Nuklearmedizin; 2009; 48(1):37-43. PubMed ID: 19212610
[TBL] [Abstract][Full Text] [Related]
4. 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals.
Ketring AR
Int J Rad Appl Instrum B; 1987; 14(3):223-32. PubMed ID: 3117736
[TBL] [Abstract][Full Text] [Related]
5. Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study.
van Aswegen A; Roodt A; Marais J; Botha JM; Naudé H; Lötter MG; Goedhals L; Doman MJ; Otto AC
Nucl Med Commun; 1997 Jun; 18(6):582-8. PubMed ID: 9259533
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
Liepe K; Kotzerke J
Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
[TBL] [Abstract][Full Text] [Related]
7. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
Liepe K; Runge R; Kotzerke J
J Cancer Res Clin Oncol; 2005 Jan; 131(1):60-6. PubMed ID: 15449184
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.
Bayouth JE; Macey DJ; Kasi LP; Fossella FV
J Nucl Med; 1994 Jan; 35(1):63-9. PubMed ID: 7505819
[TBL] [Abstract][Full Text] [Related]
10. Radiopharmaceutical therapy of bone metastases with 89SrCl2, 186Re-HEDP and 153Sm-EDTMP: a dosimetric study using Monte Carlo simulation.
Strigari L; Sciuto R; D'Andrea M; Pasqualoni R; Benassi M; Maini CL
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1031-8. PubMed ID: 17237963
[TBL] [Abstract][Full Text] [Related]
11. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
Buffa FM; Flux GD; Guy MJ; O'Sullivan JM; McCready VR; Chittenden SJ; Dearnaley DP
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
[TBL] [Abstract][Full Text] [Related]
12. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.
Cameron PJ; Klemp PF; Martindale AA; Turner JH
Nucl Med Commun; 1999 Jul; 20(7):609-15. PubMed ID: 10423762
[TBL] [Abstract][Full Text] [Related]
13. Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP.
van Rensburg AJ; Alberts AS; Louw WK
J Nucl Med; 1998 Dec; 39(12):2110-5. PubMed ID: 9867152
[TBL] [Abstract][Full Text] [Related]
14. [The measurement of 153Sm-EDTMP bone uptake rate and its relationship with therapeutic effect].
Li L; Liang Z; Deng H; Li Y; Zhang X; Yang X
Hua Xi Yi Ke Da Xue Xue Bao; 2001 Sep; 32(3):446-8. PubMed ID: 12536590
[TBL] [Abstract][Full Text] [Related]
15. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients.
Sciuto R; Festa A; Pasqualoni R; Semprebene A; Rea S; Bergomi S; Maini CL
Breast Cancer Res Treat; 2001 Mar; 66(2):101-9. PubMed ID: 11437096
[TBL] [Abstract][Full Text] [Related]
16. Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer.
Graham MC; Scher HI; Liu GB; Yeh SD; Curley T; Daghighian F; Goldsmith SJ; Larson SM
Clin Cancer Res; 1999 Jun; 5(6):1307-18. PubMed ID: 10389913
[TBL] [Abstract][Full Text] [Related]
17. High-dose treatment with (186)Re-HEDP or (153)Sm-EDTMP combined with amifostine in a rabbit model.
Brenner W; Kampen WU; von Forstner C; Brümmer C; Zuhayra M; Muhle C; Czech N; Henze E
J Nucl Med; 2001 Oct; 42(10):1545-50. PubMed ID: 11585871
[TBL] [Abstract][Full Text] [Related]
18. Development of bone seeker radiopharmaceuticals by Scandium-47 and estimation of human absorbed dose.
Deilami-Nezhad L; Moghaddam-Banaem L; Sadeghi M
Appl Radiat Isot; 2017 Nov; 129():108-116. PubMed ID: 28843158
[TBL] [Abstract][Full Text] [Related]
19. Samarium-153-EDTMP biodistribution and dosimetry estimation.
Eary JF; Collins C; Stabin M; Vernon C; Petersdorf S; Baker M; Hartnett S; Ferency S; Addison SJ; Appelbaum F
J Nucl Med; 1993 Jul; 34(7):1031-6. PubMed ID: 7686217
[TBL] [Abstract][Full Text] [Related]
20. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]